News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Molecular Devices, Inc. (MDCC) Introduces FLIPR Calcium 6 Assay Kits


4/23/2013 12:14:58 PM

Sunnyvale, California, April 23 2013 – Molecular Devices announced today the launch of FLIPR® Calcium 6 Assay Kits, the latest addition to their extensive range of calcium assay kits to address diversified GPCR and ion channel targets. Featuring a proprietary fluorophore, the dye offers the highest quantum yield of any calcium indicator on the market, delivering the greatest signal window available in a calcium assay kit. This substantial increase in signal enables researchers to monitor low-responders, including biorelevant reactions from endogenous, primary or stem cell targets.

FLIPR 6 Calcium Assay Kits provide a comprehensive method for detecting intracellular calcium changes in a simple and reliable homogeneous assay format. Combining the novel fluorophore with proven proprietary quench technology, the new assay affords the highest signal to background ratio. The unique dye is more resistant to anion-exchange proteins, enabling measurement with minimal to no probenecid, an exchange inhibitor, when studying cell lines containing an organic anion transporter.

Using a quench-free protocol, the FLIPR Calcium 6-QF Formulation allows assay performance without a masking technology, making it an ideal choice for quench-sensitive applications such as targets sensitive to quenchers or multiplexing with luminescent indicators. The new kits support GPCR targets that can be run on Molecular Devices’ FLIPR® Tetra and FlexStation® 3 Instrumentation.

Klaus Lun, Vice President of Product Marketing at Molecular Devices commented: “We are committed to providing a strong product pipeline, not only in instrumentation but also in reagents. The introduction of the new FLIPR 6 Calcium Assay Kits opens the door for researchers to assay the low-responding and more challenging targets. As we continue to move forward our goal is to enable researchers to screen more biorelevant assays and to further explore new assay dynamics including beat rate for cardiotoxicity studies. ”

Please visit www.moleculardevices.com/FLIPR_Calcium6 for more details and to request an evaluation sample

For high resolution image please email sarah.jeffery@zymecommunications.com

Contacts

Media contact:

Sarah Jeffery

Zyme Communications

T: +44 7771 730 919

E: sarah.jeffery@zymecommunications.com

Twitter: zymecomms

At Molecular Devices

Jennifer McKie

Vice President, Global Marketing

E: jennifer.mckie@moldev.com

T: +1 408 747 3514

About Molecular Devices, LLC

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics

Molecular Devices is committed to the continual development of innovative solutions for life science applications. The Company is headquartered in Silicon Valley with offices around the globe.

For more information about the complete product portfolio, visit www.moleculardevices.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES